Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma

Ken Shirabe, Keishi Sugimachi, Noboru Harada, Hiroto Kayashima, Takashi Maeda, Eiji Tsujita, Ryosuke Minagawa, Kiyoshi Kajiyama, Shohei Yoshiya, Yoshihiko Maehara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND: A sustained virological response (SVR) to interferon (IFN) therapy for chronic hepatitis C virus (HCV) reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). The prognosis after hepatectomy for HCC in patients with SVR has not been fully clarified.

PATIENTS AND METHODS: Between 1998 and 2011, 494 patients with chronic hepatitis C underwent hepatic resection for HCC at four high-volume Centers in Japan. Out of these, 188 underwent IFN therapy for HCV. In 92 patients, SVR to IFN therapy had been achieved at the time of hepatectomy (SVR group) while in 96 patients, SVR had not (non-SVR group) had not been achieved. In the other 306 patients, IFN therapy had never been performed at all (no IFN group). The clinicopathological factors and long-term outcomes were retrospectively reviewed and compared among SVR, non-SVR and no IFN groups.

RESULTS: The mean time from achievement of SVR to hepatectomy for HCC was 6.2 years (range=2 months to 20 years). The preoperative serum alanine transaminase, albumin, prothrombin time, indocyanine green retention test at 15 min were significantly preserved in the SVR group. The overall survival and recurrence-free survival rates were significantly higher in the SVR group compared to patients in non-SVR and no IFN groups.

CONCLUSION: In patients undergoing hepatectomy for HCC, those with SVR had good liver function and a more favorable long-term prognosis than those without SVR. Early detection of HCC after SVR and meticulous hepatectomy with small blood loss is important in patients with HCC after hepatectomy.

Original languageEnglish
Pages (from-to)6963-6969
Number of pages7
JournalAnticancer research
Volume35
Issue number12
Publication statusPublished - Dec 1 2015

Fingerprint

Chronic Hepatitis C
Interferons
Antiviral Agents
Hepatocellular Carcinoma
Hepatectomy
Liver
Therapeutics
Hepacivirus
Indocyanine Green
Prothrombin Time
Alanine Transaminase
Albumins
Japan
Survival Rate
Recurrence
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma. / Shirabe, Ken; Sugimachi, Keishi; Harada, Noboru; Kayashima, Hiroto; Maeda, Takashi; Tsujita, Eiji; Minagawa, Ryosuke; Kajiyama, Kiyoshi; Yoshiya, Shohei; Maehara, Yoshihiko.

In: Anticancer research, Vol. 35, No. 12, 01.12.2015, p. 6963-6969.

Research output: Contribution to journalArticle

Shirabe, K, Sugimachi, K, Harada, N, Kayashima, H, Maeda, T, Tsujita, E, Minagawa, R, Kajiyama, K, Yoshiya, S & Maehara, Y 2015, 'Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma', Anticancer research, vol. 35, no. 12, pp. 6963-6969.
Shirabe, Ken ; Sugimachi, Keishi ; Harada, Noboru ; Kayashima, Hiroto ; Maeda, Takashi ; Tsujita, Eiji ; Minagawa, Ryosuke ; Kajiyama, Kiyoshi ; Yoshiya, Shohei ; Maehara, Yoshihiko. / Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma. In: Anticancer research. 2015 ; Vol. 35, No. 12. pp. 6963-6969.
@article{484580fc29da4030a53fc25ba0cfa0a3,
title = "Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma",
abstract = "BACKGROUND: A sustained virological response (SVR) to interferon (IFN) therapy for chronic hepatitis C virus (HCV) reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). The prognosis after hepatectomy for HCC in patients with SVR has not been fully clarified.PATIENTS AND METHODS: Between 1998 and 2011, 494 patients with chronic hepatitis C underwent hepatic resection for HCC at four high-volume Centers in Japan. Out of these, 188 underwent IFN therapy for HCV. In 92 patients, SVR to IFN therapy had been achieved at the time of hepatectomy (SVR group) while in 96 patients, SVR had not (non-SVR group) had not been achieved. In the other 306 patients, IFN therapy had never been performed at all (no IFN group). The clinicopathological factors and long-term outcomes were retrospectively reviewed and compared among SVR, non-SVR and no IFN groups.RESULTS: The mean time from achievement of SVR to hepatectomy for HCC was 6.2 years (range=2 months to 20 years). The preoperative serum alanine transaminase, albumin, prothrombin time, indocyanine green retention test at 15 min were significantly preserved in the SVR group. The overall survival and recurrence-free survival rates were significantly higher in the SVR group compared to patients in non-SVR and no IFN groups.CONCLUSION: In patients undergoing hepatectomy for HCC, those with SVR had good liver function and a more favorable long-term prognosis than those without SVR. Early detection of HCC after SVR and meticulous hepatectomy with small blood loss is important in patients with HCC after hepatectomy.",
author = "Ken Shirabe and Keishi Sugimachi and Noboru Harada and Hiroto Kayashima and Takashi Maeda and Eiji Tsujita and Ryosuke Minagawa and Kiyoshi Kajiyama and Shohei Yoshiya and Yoshihiko Maehara",
year = "2015",
month = "12",
day = "1",
language = "English",
volume = "35",
pages = "6963--6969",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma

AU - Shirabe, Ken

AU - Sugimachi, Keishi

AU - Harada, Noboru

AU - Kayashima, Hiroto

AU - Maeda, Takashi

AU - Tsujita, Eiji

AU - Minagawa, Ryosuke

AU - Kajiyama, Kiyoshi

AU - Yoshiya, Shohei

AU - Maehara, Yoshihiko

PY - 2015/12/1

Y1 - 2015/12/1

N2 - BACKGROUND: A sustained virological response (SVR) to interferon (IFN) therapy for chronic hepatitis C virus (HCV) reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). The prognosis after hepatectomy for HCC in patients with SVR has not been fully clarified.PATIENTS AND METHODS: Between 1998 and 2011, 494 patients with chronic hepatitis C underwent hepatic resection for HCC at four high-volume Centers in Japan. Out of these, 188 underwent IFN therapy for HCV. In 92 patients, SVR to IFN therapy had been achieved at the time of hepatectomy (SVR group) while in 96 patients, SVR had not (non-SVR group) had not been achieved. In the other 306 patients, IFN therapy had never been performed at all (no IFN group). The clinicopathological factors and long-term outcomes were retrospectively reviewed and compared among SVR, non-SVR and no IFN groups.RESULTS: The mean time from achievement of SVR to hepatectomy for HCC was 6.2 years (range=2 months to 20 years). The preoperative serum alanine transaminase, albumin, prothrombin time, indocyanine green retention test at 15 min were significantly preserved in the SVR group. The overall survival and recurrence-free survival rates were significantly higher in the SVR group compared to patients in non-SVR and no IFN groups.CONCLUSION: In patients undergoing hepatectomy for HCC, those with SVR had good liver function and a more favorable long-term prognosis than those without SVR. Early detection of HCC after SVR and meticulous hepatectomy with small blood loss is important in patients with HCC after hepatectomy.

AB - BACKGROUND: A sustained virological response (SVR) to interferon (IFN) therapy for chronic hepatitis C virus (HCV) reduces but does not eliminate the risk of hepatocellular carcinoma (HCC). The prognosis after hepatectomy for HCC in patients with SVR has not been fully clarified.PATIENTS AND METHODS: Between 1998 and 2011, 494 patients with chronic hepatitis C underwent hepatic resection for HCC at four high-volume Centers in Japan. Out of these, 188 underwent IFN therapy for HCV. In 92 patients, SVR to IFN therapy had been achieved at the time of hepatectomy (SVR group) while in 96 patients, SVR had not (non-SVR group) had not been achieved. In the other 306 patients, IFN therapy had never been performed at all (no IFN group). The clinicopathological factors and long-term outcomes were retrospectively reviewed and compared among SVR, non-SVR and no IFN groups.RESULTS: The mean time from achievement of SVR to hepatectomy for HCC was 6.2 years (range=2 months to 20 years). The preoperative serum alanine transaminase, albumin, prothrombin time, indocyanine green retention test at 15 min were significantly preserved in the SVR group. The overall survival and recurrence-free survival rates were significantly higher in the SVR group compared to patients in non-SVR and no IFN groups.CONCLUSION: In patients undergoing hepatectomy for HCC, those with SVR had good liver function and a more favorable long-term prognosis than those without SVR. Early detection of HCC after SVR and meticulous hepatectomy with small blood loss is important in patients with HCC after hepatectomy.

UR - http://www.scopus.com/inward/record.url?scp=84964693600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964693600&partnerID=8YFLogxK

M3 - Article

C2 - 26637923

AN - SCOPUS:84964693600

VL - 35

SP - 6963

EP - 6969

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -